Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) Director Bros. Advisors Lp Baker bought 500,000 shares of the stock in a transaction on Monday, December 16th. The shares were acquired at an average cost of $15.34 per share, with a total value of $7,670,000.00. Following the acquisition, the director now directly owns 9,995,274 shares in the company, valued at approximately $153,327,503.16. This trade represents a 5.27 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Bros. Advisors Lp Baker also recently made the following trade(s):
- On Friday, December 13th, Bros. Advisors Lp Baker bought 985,397 shares of Bicycle Therapeutics stock. The stock was bought at an average cost of $13.76 per share, for a total transaction of $13,559,062.72.
Bicycle Therapeutics Stock Up 0.1 %
BCYC opened at $15.14 on Wednesday. The business has a 50 day moving average of $22.62 and a 200-day moving average of $22.71. Bicycle Therapeutics plc has a 12-month low of $12.17 and a 12-month high of $28.67. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -4.60 and a beta of 0.86.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. During the same period last year, the business posted ($1.26) earnings per share. The business's revenue for the quarter was down 50.0% compared to the same quarter last year. As a group, analysts expect that Bicycle Therapeutics plc will post -3.05 earnings per share for the current year.
Institutional Investors Weigh In On Bicycle Therapeutics
Is Starlink Set For The Largest IPO In History?
From Paradigm Press | Ad
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant.
Then, he did it again with Tesla… which is up more than 19,500% since 2010.
For perspective, that turns $100 invested into almost $20,000!
Click here now for the urgent details.
A number of institutional investors have recently modified their holdings of BCYC. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Bicycle Therapeutics by 0.6% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company's stock worth $17,975,000 after purchasing an additional 4,976 shares during the period. Pinnacle Associates Ltd. lifted its position in Bicycle Therapeutics by 202.2% during the second quarter. Pinnacle Associates Ltd. now owns 242,001 shares of the company's stock worth $4,898,000 after purchasing an additional 161,911 shares during the period. Natixis Advisors LLC bought a new stake in Bicycle Therapeutics during the second quarter worth about $261,000. TD Asset Management Inc grew its stake in Bicycle Therapeutics by 76.7% during the second quarter. TD Asset Management Inc now owns 97,186 shares of the company's stock worth $1,967,000 after buying an additional 42,200 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Bicycle Therapeutics by 97.2% in the second quarter. Renaissance Technologies LLC now owns 326,800 shares of the company's stock valued at $6,614,000 after acquiring an additional 161,100 shares during the last quarter. Institutional investors own 86.15% of the company's stock.
Analysts Set New Price Targets
Several brokerages have commented on BCYC. HC Wainwright lowered their target price on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a "buy" rating for the company in a research note on Monday. Stephens began coverage on shares of Bicycle Therapeutics in a report on Friday, November 8th. They set an "equal weight" rating and a $25.00 target price on the stock. JMP Securities reaffirmed a "market outperform" rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a research note on Monday, September 16th. B. Riley cut their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating on the stock in a research report on Friday, December 13th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $36.00.
Read Our Latest Stock Analysis on BCYC
Bicycle Therapeutics Company Profile
(
Get Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
